These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10987606)

  • 41. [Anti-arrhythmic drugs interaction and defibrillation threshold in patients with implantable cardioverter defibrillator].
    de Vasconcelos JT; Galvão Filho Sdos S; Barcellos CM
    Arq Bras Cardiol; 2003 Mar; 80(3):336-9. PubMed ID: 12856278
    [No Abstract]   [Full Text] [Related]  

  • 42. [Utilization of implantable ventricular defibrillators (with an analysis of the value of antiarrhythmics in the treatment of potentially fatal ventricular arrhythmias].
    Waleffe A
    Rev Med Liege; 2000 Apr; 55(4):307-14. PubMed ID: 10909319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overcoming the defects of a virtue: dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.
    Sweeney MO
    Circulation; 2006 Jun; 113(25):2862-4. PubMed ID: 16801472
    [No Abstract]   [Full Text] [Related]  

  • 44. Management of malignant ventricular arrhythmias and cardiac arrest.
    Fogel RI; Prystowsky EN
    Crit Care Med; 2000 Oct; 28(10 Suppl):N165-9. PubMed ID: 11055686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Are implantable cardioverter-defibrillators or drugs more effective in prolonging life? The Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial Executive Committee.
    Am J Cardiol; 1997 Mar; 79(5):661-3. PubMed ID: 9068527
    [No Abstract]   [Full Text] [Related]  

  • 46. Ventricular arrhythmias. Preventing sudden death with drugs and ICD devices.
    Doherty JU; Fuchs S; Tecce MA
    Geriatrics; 2000 Aug; 55(8):26-8, 31-2, 35-6. PubMed ID: 10953684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fundamental principle in therapy for arrhythmia].
    Atarashi H
    Nihon Naika Gakkai Zasshi; 2006 Feb; 95(2):228-33. PubMed ID: 16536071
    [No Abstract]   [Full Text] [Related]  

  • 48. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
    Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
    Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perioperative cardiac arrhythmias.
    Thompson A; Balser JR
    Br J Anaesth; 2004 Jul; 93(1):86-94. PubMed ID: 15145821
    [No Abstract]   [Full Text] [Related]  

  • 50. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
    Patel C; Yan GX; Kocovic D; Kowey PR
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
    [No Abstract]   [Full Text] [Related]  

  • 51. Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest?
    Zipes DP
    Circulation; 1995 Apr; 91(8):2115-7. PubMed ID: 7697837
    [No Abstract]   [Full Text] [Related]  

  • 52. Anger and arrhythmias.
    Schalij MJ; van Erven L
    Heart Rhythm; 2007 Mar; 4(3):274-6. PubMed ID: 17341386
    [No Abstract]   [Full Text] [Related]  

  • 53. Arrhythmias in 2015: Advances in drug, ablation, and device therapy for cardiac arrhythmias.
    Macle L; Nattel S
    Nat Rev Cardiol; 2016 Feb; 13(2):67-8. PubMed ID: 26727299
    [No Abstract]   [Full Text] [Related]  

  • 54. Management of ventricular arrhythmias.
    Aronow WS
    Compr Ther; 2008; 34(2):89-99. PubMed ID: 18833785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Ventricular arrhythmias after myocardial infarction: risk classification and treatment concepts].
    Seidl K; Hauer B; Schwick N; Buechele T; Schilling I; Senges J
    Dtsch Med Wochenschr; 1995 May; 120(18):656-60. PubMed ID: 7750434
    [No Abstract]   [Full Text] [Related]  

  • 56. Guidelines for the use of implantable cardioverter defibrillators. A Task Force of the Working Groups on Cardiac Arrhythmias and Cardiac Pacing of the European Society of Cardiology.
    Eur Heart J; 1992 Oct; 13(10):1304-10. PubMed ID: 1396800
    [No Abstract]   [Full Text] [Related]  

  • 57. Update on arrhythmias and cardiac pacing 2013.
    Almendral J; Pombo M; Martínez-Alday J; González-Rebollo JM; Rodríguez-Font E; Martínez-Ferrer J; Castellanos E; García-Fernández FJ; Ruiz-Mateas F
    Rev Esp Cardiol (Engl Ed); 2014 Apr; 67(4):294-304. PubMed ID: 24774592
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG; Dougherty CM; MacMurdy KS; Raitt MH
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):739-47. PubMed ID: 22773022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question?
    Josephson M; Nisam S
    Am J Cardiol; 1996 Apr; 77(10):859-63. PubMed ID: 8623740
    [No Abstract]   [Full Text] [Related]  

  • 60. Current management of ventricular arrhythmias.
    Anderson MH
    Br J Hosp Med; 1994 Sep 7-20; 52(5):204-9. PubMed ID: 7529627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.